ALX Oncology Announces First Patient Dosed in ASPEN-05, a Phase 1/2 Study of Evorpacept in Combination with Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia

NEXT STORY
Global Biospecimen Contract Research Services Markets, 2021-2030: Therapeutic Area, Type of Biospecimen, Type of Biospecimen for Non-Oncological Studies
PREV STORY
Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Breast Cancer Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth And Change To 2030

author_avatar
NASDAQ Market News

Timber Pharmaceuticals Reports Positive Top-line Results from Phase 2b CONTROL Study Evaluating TMB-001 in Moderate to Severe Congenital Ichthyosis

author_avatar
NASDAQ Market News

Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan for Treatment of Bullous Pemphigoid

author_avatar
NASDAQ Market News